2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Metabolic Diseases D008659 12 associated lipids
Phenylketonurias D010661 7 associated lipids
Hyperoxaluria D006959 3 associated lipids
Tyrosinemias D020176 2 associated lipids
Canavan Disease D017825 2 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Rohle D et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. 2013 Science pmid:23558169
Juratli TA et al. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. 2013 Neuro-oncology pmid:23410661
Losman JA et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. 2013 Science pmid:23393090
Ward PS et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. 2013 J. Biol. Chem. pmid:23264629
Jin G et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 2013 Cancer Res. pmid:23204232
Pollyea DA et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. 2013 Leuk. Lymphoma pmid:22680765
Tomlinson L et al. Cannabinoid receptor antagonist-induced striated muscle toxicity and ethylmalonic-adipic aciduria in beagle dogs. 2012 Toxicol. Sci. pmid:22821849
Durán RV and Hall MN Glutaminolysis feeds mTORC1. 2012 Cell Cycle pmid:23095634
Lazovic J et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. 2012 Neuro-oncology pmid:23090985
Fathi AT et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. 2012 Blood pmid:23074281
Grassian AR et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). 2012 J. Biol. Chem. pmid:23038259
Yang H et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. 2012 Clin. Cancer Res. pmid:23071358
Sasaki M et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. 2012 Genes Dev. pmid:22925884
Yang M et al. The emerging role of fumarate as an oncometabolite. 2012 Front Oncol pmid:22866264
Farias FH et al. A L2HGDH initiator methionine codon mutation in a Yorkshire terrier with L-2-hydroxyglutaric aciduria. 2012 BMC Vet. Res. pmid:22834903
Riedel TJ et al. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. 2012 Biochim. Biophys. Acta pmid:22771891
Smolková K and Ježek P The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. 2012 Int J Cell Biol pmid:22675360
Maier A et al. Transgenic Introduction of a Glycolate Oxidative Cycle into A. thaliana Chloroplasts Leads to Growth Improvement. 2012 Front Plant Sci pmid:22639647
Leonardi R et al. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. 2012 J. Biol. Chem. pmid:22442146
Kalinina J et al. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. 2012 J. Mol. Med. pmid:22426639
Chotirat S et al. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. 2012 J Hematol Oncol pmid:22397365
Kranendijk M et al. Progress in understanding 2-hydroxyglutaric acidurias. 2012 J. Inherit. Metab. Dis. pmid:22391998
Constantin A et al. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. 2012 Artif Intell Med pmid:22387185
Kunimoto H et al. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. 2012 Sci Rep pmid:22355785
Lu C et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. 2012 Nature pmid:22343901
Koivunen P et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. 2012 Nature pmid:22343896
Kleessen S et al. Model-based confirmation of alternative substrates of mitochondrial electron transport chain. 2012 J. Biol. Chem. pmid:22334689
Chow LM and Baker SJ Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. 2012 Oncotarget pmid:22287481
Choi C et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. 2012 Nat. Med. pmid:22281806
Bleeker FE et al. Recent advances in the molecular understanding of glioblastoma. 2012 J. Neurooncol. pmid:22270850
Shaw RJ and Cantley LC Decoding key nodes in the metabolism of cancer cells: sugar & spice and all things nice. 2012 F1000 Biol Rep pmid:22242042
Elkhaled A et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. 2012 Sci Transl Med pmid:22238333
Andronesi OC et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. 2012 Sci Transl Med pmid:22238332
Muñoz-Pinedo C et al. Cancer metabolism: current perspectives and future directions. 2012 Cell Death Dis pmid:22237205
Cairns RA et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. 2012 Blood pmid:22215888
Li Y et al. Combined inactivation of the Clostridium cellulolyticum lactate and malate dehydrogenase genes substantially increases ethanol yield from cellulose and switchgrass fermentations. 2012 Biotechnol Biofuels pmid:22214220
Borger DR et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. 2012 Oncologist pmid:22180306
Luchman HA et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. 2012 Neuro-oncology pmid:22166263
Borodovsky A et al. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. 2012 Curr Opin Oncol pmid:22080945
Pope WB et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. 2012 J. Neurooncol. pmid:22015945
Ward PS et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. 2012 Oncogene pmid:21996744
Capper D et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. 2012 Int. J. Cancer pmid:21913188
Tefferi A et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. 2012 Leukemia pmid:21912393
Fathi AT and Abdel-Wahab O Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. 2012 Adv Hematol pmid:21811504
Lecoeur H et al. HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. 2012 Cell Death Dis pmid:22419111
Parthasarathy A et al. Substrate specificity of 2-hydroxyglutaryl-CoA dehydratase from Clostridium symbiosum: toward a bio-based production of adipic acid. 2011 Biochemistry pmid:21434666
Reitman ZJ et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21289278
Saccenti E et al. Simplivariate models: uncovering the underlying biology in functional genomics data. 2011 PLoS ONE pmid:21698241
Fong MY et al. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. 2011 PLoS ONE pmid:21625518
Mascarenhas J et al. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. 2011 Clin Epigenetics pmid:22704337
Bhatia S et al. Mycosporine and mycosporine-like amino acids: A paramount tool against ultra violet irradiation. 2011 Pharmacogn Rev pmid:22279371
D'Alò F et al. Similarities and differences between therapy-related and elderly acute myeloid leukemia. 2011 Mediterr J Hematol Infect Dis pmid:22220249
Bosch AM et al. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. 2011 J. Inherit. Metab. Dis. pmid:21110228
Willquist K et al. Reassessment of hydrogen tolerance in Caldicellulosiruptor saccharolyticus. 2011 Microb. Cell Fact. pmid:22189215
Kaelin WG Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. 2011 Cold Spring Harb. Symp. Quant. Biol. pmid:22089927
Nieto-Sampedro M et al. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. 2011 Clin Med Insights Oncol pmid:22084619
Vogel RF et al. Genomic analysis reveals Lactobacillus sanfranciscensis as stable element in traditional sourdoughs. 2011 Microb. Cell Fact. pmid:21995419
Guo C et al. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. 2011 Curr. Opin. Neurol. pmid:22002076
Schulz N et al. Role of medium- and short-chain L-3-hydroxyacyl-CoA dehydrogenase in the regulation of body weight and thermogenesis. 2011 Endocrinology pmid:21990309
Takahashi S Current findings for recurring mutations in acute myeloid leukemia. 2011 J Hematol Oncol pmid:21917154
Haffner MC et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. 2011 Oncotarget pmid:21896958
Kranendijk M et al. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies. 2011 Biochim. Biophys. Acta pmid:21889589
Khorassani R et al. Citramalic acid and salicylic acid in sugar beet root exudates solubilize soil phosphorus. 2011 BMC Plant Biol. pmid:21871058
Ohka F et al. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. 2011 PLoS ONE pmid:21829728
Marie SK and Shinjo SM Metabolism and brain cancer. 2011 Clinics (Sao Paulo) pmid:21779721
Araújo WL et al. Analysis of a range of catabolic mutants provides evidence that phytanoyl-coenzyme A does not act as a substrate of the electron-transfer flavoprotein/electron-transfer flavoprotein:ubiquinone oxidoreductase complex in Arabidopsis during dark-induced senescence. 2011 Plant Physiol. pmid:21788362
Scott JG et al. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? 2011 Neuro-oncology pmid:21784755
Bralten LB et al. Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. 2011 PLoS ONE pmid:21760942
Lages E et al. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. 2011 PLoS ONE pmid:21655185
Passamonti F et al. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. 2011 Oncotarget pmid:21646683
Krell D et al. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. 2011 PLoS ONE pmid:21625441
Yan W et al. Oncogene addiction in gliomas: implications for molecular targeted therapy. 2011 J. Exp. Clin. Cancer Res. pmid:21575270
Ramezani M et al. Glutamate racemization and catabolism in Fusobacterium varium. 2011 FEBS J. pmid:21575137
Zhang Y Biology of the Mi-2/NuRD Complex in SLAC (Stemness, Longevity/Ageing, and Cancer). 2011 Gene Regul Syst Bio pmid:21523247
Chowdhury R et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. 2011 EMBO Rep. pmid:21460794
Kochevenko A and Fernie AR The genetic architecture of branched-chain amino acid accumulation in tomato fruits. 2011 J. Exp. Bot. pmid:21436187
Kölker S et al. Diagnosis and management of glutaric aciduria type I--revised recommendations. 2011 J. Inherit. Metab. Dis. pmid:21431622
Jin G et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. 2011 PLoS ONE pmid:21326614
Araújo WL et al. Antisense inhibition of the iron-sulphur subunit of succinate dehydrogenase enhances photosynthesis and growth in tomato via an organic acid-mediated effect on stomatal aperture. 2011 Plant Cell pmid:21307286
Frezza C et al. Inborn and acquired metabolic defects in cancer. 2011 J. Mol. Med. pmid:21301796
Engqvist MK et al. Plant D-2-hydroxyglutarate dehydrogenase participates in the catabolism of lysine especially during senescence. 2011 J. Biol. Chem. pmid:21296880
Brauburger K et al. The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of D-, L-2-hydroxyglutarate and 3-hydroxyglutarate into neurons. 2011 J. Inherit. Metab. Dis. pmid:21264516
Xu W et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. 2011 Cancer Cell pmid:21251613
Lu Y et al. Chloroplast 2010: a database for large-scale phenotypic screening of Arabidopsis mutants. 2011 Plant Physiol. pmid:21224340
Rellán-Álvarez R et al. Metabolite profile changes in xylem sap and leaf extracts of strategy I plants in response to iron deficiency and resupply. 2011 Front Plant Sci pmid:22645546
Fernie AR and Klee HJ The use of natural genetic diversity in the understanding of metabolic organization and regulation. 2011 Front Plant Sci pmid:22645543
Tohge T et al. From models to crop species: caveats and solutions for translational metabolomics. 2011 Front Plant Sci pmid:22639601
Paravati AJ et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. 2011 J. Neurooncol. pmid:21181233
O'Keefe LV et al. Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. 2011 Hum. Mol. Genet. pmid:21075834
Gross S et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. 2010 J. Exp. Med. pmid:20142433
Maxmen A Cancers converge at 2-HG. 2010 J. Exp. Med. pmid:20142426
Kones R Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. 2010 Drug Des Devel Ther pmid:21267417
Abdel-Wahab O and Levine RL Metabolism and the leukemic stem cell. 2010 J. Exp. Med. pmid:20368582
Figueroa ME et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. 2010 Cancer Cell pmid:21130701
Seltzer MJ et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. 2010 Cancer Res. pmid:21045145
Kranendijk M et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. 2010 Science pmid:20847235
Riemenschneider MJ et al. Molecular diagnostics of gliomas: state of the art. 2010 Acta Neuropathol. pmid:20714900
Yang I and Liau LM American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA. 2010 J. Neurooncol. pmid:20714783
Dang L et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. 2010 Nature pmid:20559394
Reitman ZJ and Yan H Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. 2010 J. Natl. Cancer Inst. pmid:20513808